Price
No data yet.
Social Signal Score
Revenue
$692.0K-97.50%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael S. Exton
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Beta
- 1.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.02
Financials
Revenue
$692.0K-97.5%Net Income
$-31.77MEBITDA
$-29.06MFree Cash Flow
$-23.92MEPS (diluted)
$-0.07Shares Outstanding (diluted)
437.65M+321.3%Operating Expenses
$27.19MCash & Debt
$190.61MReturn of Capital
$0.00Revenue by Segment (annual)
$49.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $49.80M | $-50.34M | $-0.14 |
| 2024 | $31.08M | $-200.40M | $-0.63 |
| 2023 | $1.20M | $-177.12M | $-0.80 |
| 2022 | $139.0K | $-101.94M | $-0.62 |
| 2021 | $298.0K | $-87.76M | $-0.61 |
| 2020 | $24.00M | $-58.57M | $-0.63 |
| 2019 | $322.07M | $130.13M | $1.23 |
| 2018 | $63.21M | $-120.55M | $-1.14 |
| 2017 | $90.33M | $-129.05M | $-1.23 |
| 2016 | $83.34M | $-141.43M | $-1.36 |
| 2015 | $130.01M | $-4.68M | $-0.05 |
| 2014 | $22.85M | $-100.29M | $-1.31 |
| 2013 | $2.22M | $-104.13M | $-1.42 |
| 2012 | $1.09M | $-110.21M | $-1.58 |
Valuation
LXRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.06 per share
Typical surprise +42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.06 vs $-0.05miss
- Thu, May 7$-0.00 vs $-0.04beat
- Thu, Mar 5$-0.04 vs $-0.07beat
- Thu, Nov 6$-0.04 vs $-0.07beat
- Wed, Aug 6$0.01 vs $-0.08beat
- Tue, May 13$-0.07 vs $-0.10beat
Estimates and results for LXRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LXRX officers and directors.
- Bought
- $723k
- Sold
- —
7 trades
0 trades
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.